Medpace Holdings, Inc. $MEDP Shares Sold by Mawer Investment Management Ltd.

Mawer Investment Management Ltd. cut its holdings in shares of Medpace Holdings, Inc. (NASDAQ:MEDP) by 37.0% during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 407,302 shares of the company’s stock after selling 239,472 shares during the quarter. Medpace accounts for 1.3% of Mawer Investment Management Ltd.’s investment portfolio, making the stock its 23rd largest position. Mawer Investment Management Ltd.’s holdings in Medpace were worth $228,761,000 as of its most recent SEC filing.

Other hedge funds also recently added to or reduced their stakes in the company. Cibc World Market Inc. acquired a new stake in Medpace during the 3rd quarter worth approximately $5,033,000. Dorsey Wright & Associates acquired a new stake in Medpace during the 3rd quarter worth approximately $5,082,000. Capital Fund Management S.A. lifted its holdings in Medpace by 129.5% during the 3rd quarter. Capital Fund Management S.A. now owns 32,412 shares of the company’s stock worth $16,665,000 after buying an additional 18,287 shares in the last quarter. Victory Capital Management Inc. lifted its holdings in Medpace by 32.9% during the 3rd quarter. Victory Capital Management Inc. now owns 30,539 shares of the company’s stock worth $15,702,000 after buying an additional 7,565 shares in the last quarter. Finally, Fisher Asset Management LLC lifted its holdings in Medpace by 9.9% during the 3rd quarter. Fisher Asset Management LLC now owns 137,746 shares of the company’s stock worth $70,824,000 after buying an additional 12,399 shares in the last quarter. 77.98% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity at Medpace

In other Medpace news, General Counsel Stephen P. Ewald sold 16,349 shares of Medpace stock in a transaction that occurred on Thursday, May 28th. The stock was sold at an average price of $450.00, for a total transaction of $7,357,050.00. Following the transaction, the general counsel owned 20,343 shares of the company’s stock, valued at $9,154,350. The trade was a 44.56% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Also, President Jesse J. Geiger sold 31,707 shares of Medpace stock in a transaction that occurred on Tuesday, March 17th. The stock was sold at an average price of $455.30, for a total value of $14,436,197.10. Following the transaction, the president directly owned 15,000 shares in the company, valued at approximately $6,829,500. This trade represents a 67.88% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders own 20.50% of the company’s stock.

Medpace Price Performance

NASDAQ MEDP opened at $451.47 on Tuesday. The firm’s fifty day moving average price is $457.28 and its 200 day moving average price is $512.30. The company has a market capitalization of $12.89 billion, a price-to-earnings ratio of 28.38, a price-to-earnings-growth ratio of 2.27 and a beta of 1.19. Medpace Holdings, Inc. has a 12 month low of $291.28 and a 12 month high of $628.92.

Medpace (NASDAQ:MEDP) last posted its earnings results on Wednesday, April 22nd. The company reported $4.28 EPS for the quarter, beating analysts’ consensus estimates of $3.74 by $0.54. The firm had revenue of $706.60 million for the quarter, compared to the consensus estimate of $697.82 million. Medpace had a net margin of 17.19% and a return on equity of 120.89%. The company’s revenue was up 26.5% on a year-over-year basis. During the same period last year, the firm posted $3.67 EPS. Medpace has set its FY 2026 guidance at 16.680-17.500 EPS. As a group, sell-side analysts forecast that Medpace Holdings, Inc. will post 17.04 earnings per share for the current year.

Wall Street Analyst Weigh In

MEDP has been the topic of a number of research reports. Wall Street Zen lowered shares of Medpace from a “buy” rating to a “hold” rating in a report on Saturday, April 25th. Truist Financial dropped their price objective on shares of Medpace from $555.00 to $539.00 and set a “hold” rating on the stock in a research report on Wednesday, February 11th. Barclays dropped their price objective on shares of Medpace from $500.00 to $450.00 and set an “equal weight” rating on the stock in a research report on Friday, April 24th. Mizuho set a $582.00 price objective on shares of Medpace in a research report on Wednesday, February 11th. Finally, TD Cowen raised shares of Medpace from a “sell” rating to a “hold” rating and dropped their price objective for the company from $462.00 to $419.00 in a research report on Wednesday, February 18th. Four analysts have rated the stock with a Buy rating, ten have issued a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, Medpace currently has a consensus rating of “Hold” and an average target price of $467.08.

Key Stories Impacting Medpace

Here are the key news stories impacting Medpace this week:

• Negative Sentiment: Multiple law firms, including Rosen, Faruqi & Faruqi, Levi & Korsinsky, the Schall Law Firm, DJS Law Group, and others, reminded investors that a class action has been filed against Medpace and certain officers, keeping legal overhang and potential liability in focus. Article: MEDP Investors Have Opportunity to Lead Medpace Holdings, Inc. Securities Fraud Lawsuit
• Negative Sentiment: The lawsuit reminders may reinforce concerns that Medpace could face damages, legal costs, or reputational pressure if the allegations gain traction. Article: MEDP Investor Alert: Medpace Holdings Inc. Securities Fraud Lawsuit
• Neutral Sentiment: One disclosed insider transaction showed Medpace General Counsel Stephen P. Ewald sold 16,349 shares at $450 each, a move that may draw investor attention but does not by itself establish a broader business trend. Article: SEC Form 4 filing for Stephen P. Ewald

Medpace Company Profile

Medpace Holdings, Inc (NASDAQ: MEDP) is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.

Medpace’s core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing.